Tuesday, 21 October 2025
  
Login

Australia's most trusted
source of pharma news

Tuesday, 21 October 2025
News

Lilly counts grim cost of PBS delays

Posted 20 October 2025 PM

It's been hailed as a new era in treatment for breast cancer patients, but the grim reality is that a punishing 650 day wait for a PBS listing for Lilly's Verzenio, left 3500 Australian women without funded access to the drug.

According to seven-year data from the landmark monarchE trial, two years of treatment with Verzenio in combination with endocrine therapy (ET) reduces the relative risk of death by 15.8 per cent compared to ET alone in patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), node- positive, high-risk early breast cancer.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (2)

Sales & Customer Relations (13)

Clinical & Medical, R&D (5)

Regulatory, Pharmacovigilance & QA (1)

Other (11)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.